Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Intravenous Carboplatin/Paclitaxel or Intravenous and Intraperitoneal Paclitaxel/Cisplatin in Combination With Continuous or Intermittent /CTEP-Supplied Agent ABT-888 (NSC #737664) and CTEP-Supplied Agent Bevacizumab (NSC #704865) in Newly Diagnosed Patients With Previously Untreated Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT00989651 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00989651
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00989651 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Intravenous Carboplatin/Paclitaxel or Intravenous and Intraperitoneal Paclitaxel/Cisplatin in Combination With Continuous or Intermittent /CTEP-Supplied Agent ABT-888 (NSC #737664) and CTEP-Supplied Agent Bevacizumab (NSC #704865) in Newly Diagnosed Patients With Previously Untreated Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Completed
Start date
October 28, 2009
Completion date
April 10, 2020
Enrollment
431 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

fallopian tube carcinoma, fallopian tube carcinosarcoma, fallopian tube clear cell adenocarcinoma, fallopian tube endometrioid adenocarcinoma, fallopian tube mucinous adenocarcinoma, fallopian tube serous neoplasm, fallopian tube transitional cell carcinoma, fallopian tube undifferentiated carcinoma, ovarian brenner tumor, ovarian carcinoma, ovarian carcinosarcoma, ovarian clear cell adenocarcinoma, ovarian endometrioid adenocarcinoma, ovarian mucinous adenocarcinoma, ovarian seromucinous tumor, ovarian serous adenocarcinoma, ovarian transitional cell carcinoma, ovarian undifferentiated carcinoma, primary peritoneal carcinoma, primary peritoneal serous adenocarcinoma, stage iia fallopian tube cancer ajcc v6 and v7, stage iia ovarian cancer ajcc v6 and v7, stage iib fallopian tube cancer ajcc v6 and v7, stage iib ovarian cancer ajcc v6 and v7, stage iic fallopian tube cancer ajcc v6 and v7, stage iic ovarian cancer ajcc v6 and v7, stage iiia fallopian tube cancer ajcc v7, stage iiia ovarian cancer ajcc v6 and v7, stage iiia primary peritoneal cancer ajcc v7, stage iiib fallopian tube cancer ajcc v7, stage iiib ovarian cancer ajcc v6 and v7, stage iiib primary peritoneal cancer ajcc v7, stage iiic fallopian tube cancer ajcc v7, stage iiic ovarian cancer ajcc v6 and v7, stage iiic primary peritoneal cancer ajcc v7, stage iv fallopian tube cancer ajcc v6 and v7, stage iv ovarian cancer ajcc v6 and v7, stage iv primary peritoneal cancer ajcc v7